- Home
- BAFN vs MRSN Comparison
BAFN vs MRSN Comparison
Compare BAFN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- MRSN
- Stock Information
- Founded
- BAFN 1999
- MRSN 2001
- Country
- BAFN United States
- MRSN United States
- Employees
- BAFN N/A
- MRSN N/A
- Industry
- BAFN Savings Institutions
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- MRSN Health Care
- Exchange
- BAFN Nasdaq
- MRSN Nasdaq
- Market Cap
- BAFN 70.2M
- MRSN 71.9M
- IPO Year
- BAFN N/A
- MRSN 2017
- Fundamental
- Price
- BAFN $16.36
- MRSN $0.31
- Analyst Decision
- BAFN
- MRSN Buy
- Analyst Count
- BAFN 0
- MRSN 3
- Target Price
- BAFN N/A
- MRSN $4.00
- AVG Volume (30 Days)
- BAFN 10.9K
- MRSN 3.0M
- Earning Date
- BAFN 04-24-2025
- MRSN 03-03-2025
- Dividend Yield
- BAFN 1.96%
- MRSN N/A
- EPS Growth
- BAFN 134.19
- MRSN N/A
- EPS
- BAFN 2.62
- MRSN N/A
- Revenue
- BAFN $83,769,000.00
- MRSN $40,497,000.00
- Revenue This Year
- BAFN N/A
- MRSN N/A
- Revenue Next Year
- BAFN N/A
- MRSN N/A
- P/E Ratio
- BAFN $6.30
- MRSN N/A
- Revenue Growth
- BAFN 10.60
- MRSN 9.88
- 52 Week Low
- BAFN $10.40
- MRSN $0.31
- 52 Week High
- BAFN $19.75
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- BAFN 35.97
- MRSN 26.66
- Support Level
- BAFN $16.00
- MRSN $0.41
- Resistance Level
- BAFN $19.00
- MRSN $0.37
- Average True Range (ATR)
- BAFN 1.07
- MRSN 0.04
- MACD
- BAFN -0.36
- MRSN -0.00
- Stochastic Oscillator
- BAFN 18.31
- MRSN 0.00
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.